Lumida
/CRMD
⌘K
CorMedix Inc

CorMedix Inc

CRMD
$7.83USD-1.70%-0.13 today

MARKET CAP

609.9M

P/E (TTM)

3.6x

FWD P/E

DAY RANGE

$8 – $8

52W RANGE

$6
$13

AI Summary

Stalk
Sell NowMedium

CRMD is entrenched in a Stage 4 decline with a clear sequence of lower highs and lower lows. Short-term trend and EMAs are sloping downward, and price is extended below moving averages without signs of exhaustion. The medium-term bias remains bearish, unsupported by any mean-reversion eligibility, justifying an immediate sell initiation into resistance at the declining EMA regime.

  • Q2 revenue $101.9M up 100% YoY; EPS $0.29 beat $0.25 consensus; EBITDA guidance raised to $125–140M
  • Median analyst price target $15 signals ~96% upside from current levels
  • Significant price swings highlight elevated volatility risk
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2020FY 2021FY 2022FY 2024FY 2025TREND
Sales, Adj.$239,231$190,936$65,408$43.5M$311.7M
YoY %-15.5%-20.2%-65.7%+617.0%
P / Sales887.1x897.6x2573.8x11.0x3.0x
EV / Sales733.2x650.5x2020.8x10.8x3.9x
Gross Profit, Adj.$34,385$41,998$61,674$40.3M$275.7M
YoY %+138.2%+22.1%+46.8%+584.5%
Margin %14.4%22.0%94.3%92.7%88.5%
EV / Gross Profit5100.9x2957.5x2143.2x11.7x4.4x
EBITDA, Adj.$-27.1M$-29.3M$-30.4M$-22.0M$164.7M
YoY %-29.3%-8.1%-3.9%+54.9%+847.0%
Margin %-11310.6%-15324.8%-46500.3%-50.7%52.8%
EV / EBITDA-6.5x-4.2x-4.3x-21.3x7.3x
EBIT$-27.2M$-29.4M$-30.6M$-22.4M$150.1M
YoY %-29.6%-8.1%-4.0%+54.3%+771.6%
Margin %-11378.4%-15417.5%-46819.9%-51.4%48.2%
EV / EBIT-6.4x-4.2x-4.3x-21.0x8.1x
Net Income$-22.0M$-28.2M$-29.7M$-17.9M$163.1M
YoY %+49.4%-28.1%-5.3%+61.3%+1009.4%
Net Margin-9207.7%-14774.7%-45409.9%-41.2%52.3%
EPS (GAAP)-$0.77-$0.75-$0.74-$0.30$2.04
YoY %+57.2%+2.6%+1.3%+67.0%+780.0%